Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr;27(4):494-503.
doi: 10.1592/phco.27.4.494.

Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome

Matthew P Muller  1 , Linda Dresser, Janet Raboud, Allison McGeer, Elizabeth Rea, Susan E Richardson, Tony Mazzulli, Mark Loeb, Marie Louie; Canadian SARS Research Network
Affiliations

Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome

Matthew P Muller et al. Pharmacotherapy. 2007 Apr.

Abstract

Study objectives: To distinguish adverse events related to ribavirin therapy from those attributable to severe acute respiratory syndrome (SARS), and to determine the rate of potential ribavirin-related adverse events.

Design: Retrospective cohort study.

Setting: Hospitals in Toronto, Ontario, Canada.

Patients: A cohort of 306 patients with confirmed or probable SARS, 183 of whom received ribavirin and 123 of whom did not, between February 23, 2003, and July 1, 2003. Of the 183 treated patients, 155 (85%) received very high-dose ribavirin; the other 28 treated patients received lower-dose regimens.

Measurements and main results: Data on all patients with SARS admitted to hospitals in Toronto were abstracted from charts and electronic databases onto a standardized form by trained research nurses. Logistic regression was used to evaluate the association between ribavirin use and each adverse event (progressive anemia, hypomagnesemia, hypocalcemia, bradycardia, transaminitis, and hyperamylasemia) after adjusting for SARS-related prognostic factors and corticosteroid use. In the primary logistic regression analysis, ribavirin use was strongly associated with anemia (odds ratio [OR] 3.0, 99% confidence interval [CI] 1.5-6.1, p<0.0001), hypomagnesemia (OR 21, 99% CI 5.8-73, p<0.0001), and bradycardia (OR 2.3, 99% CI 1.0-5.1, p=0.007). Hypocalcemia, transaminitis, and hyperamylasemia were not associated with ribavirin use. The risk of anemia, hypomagnesemia, and bradycardia attributable to ribavirin use was 27%, 45%, and 17%, respectively.

Conclusions: High-dose ribavirin is associated with a high rate of adverse events. The use of high-dose ribavirin is appropriate only for the treatment of infectious diseases for which ribavirin has proven clinical efficacy, or in the context of a clinical trial. Ribavirin should not be used empirically for the treatment of viral syndromes of unknown origin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad‐spectrum antiviral activity of Virazole: 1‐β‐D‐ribofuranosyl‐1,2,4‐triazole‐3‐carboxamide. Science 1972;177: 705–6. - PubMed
    1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39: 1147–71. - PubMed
    1. American Academy of Pediatrics Committee on Infectious Diseases . Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993;92: 501–4. - PubMed
    1. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314: 20–6. - PubMed
    1. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double‐blind, concurrent, placebo‐controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164: 1119–27. - PubMed

Publication types

MeSH terms